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1. Introduction
Psoriasis has a profound impact on patients’ everyday life. The burden of the disease ex‐
tends beyond physical manifestations and includes significant physical, social and psycho‐
logical impairment. Numerous studies have demonstrated the significant negative impact of
psoriasis on quality of life (QoL) [1-5]. Furthermore, as a chronic disease, psoriasis affects
the QoL of both patients and their close relatives in a cumulative way [6]. The family mem‐
bers of patients with psoriasis experience a wide range of detrimental effects on their lives
with regards to psychological social and lifestyle modifications, interpersonal relationships,
financial issues, family activities, sleep and issues related to the practical care of the patients.
Various factors may contribute to the lower QoL of patients with psoriasis. The chronic na‐
ture of the disease and the lack of control over unexpected outbreaks of the symptoms are
among the most bothersome aspects of psoriasis [7]. Patients may feel humiliated when they
need to expose their bodies during intimate relationships, swimming, using public showers,
or anyway living in conditions that do not provide adequate privacy [8]. Thus psoriasis af‐
fects patients’ social life, daily activities, and sexual functioning [9]. Treatment of psoriasis,
as it may be associated with risk for adverse effects, is also an important component of the
QoL of psoriasis patients [10]. By utilizing the Short Form-36 (SF-3 6), a generic QoL instru‐
ment, it has been demonstrated that psoriasis may cause as much disability as other major
medical diseases, including heart disease, diabetes, and cancer [11].
Psoriasis is also related to several co-morbidities, especially cardiovascular diseases and
psychiatric disorders. Moreover, cardiovascular risk factors are strongly associated with the
severity of inflammation and the duration of disease [12-14].
Improving the QoL in psoriasis patients is an extremely important goal. Therefore, the inter‐
ventions to improve the process of care of this population should also assess QoL outcomes,
such as social functioning and emotional well-being, adjusting for the effects of co-existing
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chronic conditions. Disease-specific measures may be sensitive enough to detect and quanti‐
fy small changes that are important to clinicians and patients [15]. Healthcare professionals
have a crucial role in identifying and supporting affected patients and families. In order to
establish a good relationship with family members and to be able to improve patients’ com‐
pliance, dermatologists should develop greater insight into the lives of psoriasis patients
and their relatives.
In this chapter, the impact of the different aspects of psoriasis on QoL will be reviewed.
2. Skin symptoms
Research found that large percentages of patients with psoriasis reported considerably skin
pain and discomfort [16,17]. Skin pain was reported by up to 42%, and skin discomfort by
up to 37% of psoriasis patients [16, 18,19]. Skin pain and discomfort had a negative impact
on functions such as sleep, mood and enjoyment of life [16]. Studies suggested that other
psoriasis-related sensory skin symptoms were associated with sleep disturbances, psycho‐
logical distress and impaired health related QoL (HRQoL) [20-25].
Ljosaa et al. [17] showed that physiological factors such as skin pain and disease severity
were significantly associated with HRQoL and that the association between skin pain and
HRQoL was partly mediated by sleep disturbance, while less by psychological distress.
Other skin symptoms of psoriasis can significantly affect physical functioning, perception of
disease, and QoL. These symptoms include itching, “skin shedding”, tightness, redness,
dryness, and bleeding [2, 21]. In particular, a direct correlation between pruritus severity
and depression has been shown [26]. Psoriatic lesions of the vulva were found in women
with psoriasis, resulting in itching, burning and vulvar discomfort, and women with these
symptoms more frequently demonstrated depressive symptoms [27].
Psoriatic skin lesions are often perceived by patients as making their physical appearance
unsightly; skin lesions make them feeling disfigured and apprehensive that others will
avoid or exclude them, resulting in low self-esteem and self-confidence [28, 29].
When psoriasis involves the palms and soles, which occurs in approximately 40% of pa‐
tients, the pain and discomfort result in significantly greater physical disability than is expe‐
rienced by patients without palmoplantar involvement [30]. Nail involvement, which is
present in up to 50% of patients, may also limit daily activities such as basic self-care activi‐
ties and housekeeping [31, 32].
3. Psoriatic arthritis
Psoriatic arthritis (PsA) is a painful disease of the joints and connective tissue affecting
10-30% of patients with psoriasis, and is mainly localized at fingers, toes, wrists, hips and
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back [2, 3, 31, 33]. PsA can result in damage to bone and synovial membranes, pronounced
disability, and increased mortality [33]. Patients with PsA have a significantly worse QoL
than those without PsA, as measured by different questionnaires [31, 34].
4. Psychological disturbances and psychiatric co-morbidities
Psoriasis is associated with a variety of psychological difficulties, including poor self-es‐
teem, sexual dysfunction, anxiety, depression, and suicidal ideation [35]. The psychiatric
morbidity in psoriasis may be primary or secondary to the impact of the disease upon the
patients’ QoL.
High depression/anxiety scores, obsessionality and difficulties with verbal expression of
emotions, especially anger, social stigmatization, high stress levels, depression, and other
psychosocial co-morbidities experienced by patients with psoriasis are not always propor‐
tional to, or predicted by, other measurements of disease severity, such as body surface area
involvement or plaque severity [36-46]. In general, psychological disturbances, including
perception of stigmatization and depression, are stronger determinants of disability in psor‐
iasis patients than are disease severity, location and duration [47]. The Italian PSYCHAE
study, which measured psychological distress (PD) in 1580 patients with psoriasis by the
General Health Questionnaire-12 (GSQ-12) and the Brief Symptom Inventory (BSI), found
that there was no association between disease severity and PD [48].
It is not surprising that perceived stress in patients with psoriasis, as well as with other
chronic disease, predicts poorer QoL [49]. On the other hand psoriasis is generally thought
to be made worse by stress. Various studies have reported an association between stress and
psoriasis. In a study of 132 patients with psoriasis, 39% recalled a significant stressful event
within one month before the first episode of psoriasis [50]. In contrast, a more recent pro‐
spective clinical study demonstrated that there was no direct relationship between stress
and exacerbation of psoriasis, showed no clear relationship between stress levels and wor‐
sening of psoriasis and found no time relationships between stress and the appearance of
psoriasis [51]. A factor analysis of the Psoriasis Life Stress Inventory revealed two stress-re‐
lated factors contributing to the psychosocial impact of psoriasis: stress associated with an‐
ticipation of the reaction and avoidance by others, and stress associated with patients’
experience or beliefs about being evaluated exclusively on the basis of their skin [52]. So,
stress is largely secondary to the cosmetic disfigurement associated with psoriasis, with
great impact on QoL and possibly resulting in psychological morbidity.
Studies on the relationship between psychological factors and psoriasis severity have pri‐
marily been focused on depression, with conflicting results: some authors have found de‐
pression correlated with objective measures of disease severity [49], while others have not
[53]. Anyway, relatively high rates of depression are reported in patients with psoriasis [54,
55]. Controlled studies found notably higher degree of depression in patients with psoriasis
than in controls [56-58].
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Suicidal ideation and cases of completed suicide have been reported in psoriasis. The preva‐
lence of suicidal ideation has been reported to be 2.5% among less severely affected outpa‐
tients with <30% of their body surface involved and 7.2% among the more severely affected
inpatients as compared to 5.2% in acne patients, 2.1% in atopic dermatitis patients and 0% in
alopecia areata patients [57, 59]. Death wishes and suicidal ideation were associated with
higher depression scores.
Some reports suggest a higher prevalence of alcohol abuse and cigarette smoking among
psoriatic patients [60,61]. In one study, there was an 18% prevalence of alcoholism in pa‐
tients with psoriasis compared to 2% among dermatologic controls [60]. Several studies
have shown that treatment outcomes are worse in heavy drinkers [62-64]. Abstinence alone
has been shown to possibly induce psoriasis remission, whereas restarting drinking may
cause disease relapse [62, 65].
Concerning the evolution of PD in psoriasis, the longitudinal phase of the PSYCHAE study,
that specifically evaluated this aspect in 1500 psoriatic patients during up to 12 months,
showed that minor PD halved during the observation period, possibly due to improvement
of clinical symptoms, while major PD remained stable [66]. The same authors investigated
patients’ coping strategies and found that planning, active coping and acceptance were
strategies most commonly employed by their patients while denial, behavioural disengage‐
ment, and substance abuse were the least frequent attitudes [48]. During the 12-month fol‐
low-up, active coping and avoiding dramatization by recourse to humor were predictive
factors of amelioration of PD [66].
5. Stigma
A stigma is severe social disapproval of a person based on a distinguishing characteristics
[67]. It has also been defined as a biologic or social mark that sets a person off from others
[68]. Visible lesions cause feelings of stigmatization which can lead to psychological stress
and social withdrawal [69]. Psoriasis patients, even those with relatively mild symptoms, ex‐
perience high stigmatization as compared to sufferers of other skin diseases, with significant
impact on outcomes such as QoL, depression and disability [70-72]. Stigmatization has
many forms: Ginsburg and Link identified different dimensions, including anticipation of
rejection, feeling of being flawed, sensitivity to others’ attitude, guilt and shame, reduction
of self-esteem [73].
Among the themes at the basis of the stigma experience, shame has an important role. In
different studies, patients with psoriasis reported feelings of embarrassment and shame
compared to healthy controls [74, 75]. Shame is one of the most reported emotions, especial‐
ly by women and by patients with a long disease duration [74]. Feelings of shame can have a
strong impact on social life, since they can result in avoidance of public spaces, thus reduc‐
ing social opportunities, even concerning employment [76].
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Boehm et al. [67] have found that it is stigmatization that mediates between symptom se‐
verity and QoL, in particular the stigmatization parameters ‘reduction of self-esteem’ and
‘rejection’.
6. Gender
Psoriasis does not discriminate by gender. Studies generally show no difference in the se‐
verity of physical symptoms suffered by men and women. However, women and men have
different subjective perceptions of how symptoms affect their social interactions, emotional
states and, ultimately, their QoL.
Men can find it easier to distance themselves from the social effects of psoriasis. Women, in
contrast, are more likely to report feeling ‘upset’, ‘disturbed’ or ‘ashamed’ in social settings
[77]. Stress research provides another way of understanding differences between men and
women’s reactions to psoriasis. Women may be more prone to perceive stress and may be
more likely to perceive a greater impact on mental QoL [78].Other authors have shown that
women may have a higher likelihood of being stress-reactors [79]. Boehm et al. [67] have
found that women reported higher discomfort levels and higher stigmatization, and that, in
general, gender differences are observable in the mental component summary score, but not
in general-physical or skin-related QoL. The PSYCHAE study, conducted on nearly 1600
Italian psoriasis patients, found that the female gender was the most important predictive
factor for psychological distress [48].
7. Sexual health
Psoriasis may involve genital skin. In a Netherlands study, of 1943 patients with psoria‐
sis, over 45% reported genital involvement at some time during the course of the disease
[80]. Relatively few studies have evaluated the impact of psoriasis on sexual health, how‐
ever,  according  to  these  studies,  psoriasis  interferes  with  sexual  relations  in  35-50%  of
patients  [76,  81,  82].  Sexual  dysfunction and distress  are  particularly  high when genital
skin is affected.
Psoriasis has a negative influence on a patient’s desire for physical intimacy [83] and causes
decreased libido in a substantial proportion of patients [81]. Feelings of shame and embar‐
rassment about physical appearance and reduced sexual desire might play a major role in
high distress and dysfunction scores in specific sexual indexes [84]. Impairment of sexual ac‐
tivity is more profound in patients with more severe psoriatic symptoms [85], and appears
to be more prevalent in women [1]. The patients who believe psoriasis has a negative effect
on their sexual lives have more symptoms of depression [81].
Also the treatments used by patients with psoriasis may cause sexual dysfunction: some
publications report that antipsoriatic medication such as methotrexate and etretinate might
cause sexual impotence and erectile dysfunction [86-88].
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8. Impact of QoL on
healthcare resources
Psoriasis causes significant occupational disability. Over 17% of patients aged 18-54 report
psychologic effects in the workplace due to their disease [2], 6% of employed patients with
severe psoriasis reported workplace discrimination [2], and 23% reported that psoriasis af‐
fected their choice of career [9]. Problems in work were more frequent in patients with pal‐
moplantar psoriasis. Thus, it appears that psoriasis may have a negative impact on work
both for psychological and clinical reasons [2, 9]. Wu et al [89] showed that psoriasis pa‐
tients were more likely to have missed work for health-related reasons, had significantly
more health-related work productivity impairment, and more overall work impairment [90].
This can have financial consequences and may limit lifetime earning potential and career.
One study found that 86% of patients with severe psoriasis were ‘moderately’ or ‘a lot’ con‐
cerned with the time and costs of treating psoriasis [91]. Moreover, psoriasis prevents some
patients from obtaining employment altogether [92]. Two studies in the UK found a lower
rate of employment in patients with severe psoriasis [41, 92]. Patients with psoriasis who are
working, however, tend to have a low work QoL [91]. Fleischer et al [93] theorized that the
effect of psoriasis on a patient’s work life might result in reduced socio-economical standing
and limitations and 34% of the study patients reported hardships due to the financial bur‐
den of the disease.
9. Impact of QoL on healthcare resources
Poorer QoL of psoriasis patients is associated with increased healthcare resource utilization,
independent of the clinical severity of the disease [94]. As stated previously in this chapter,
measuring clinical severity of skin lesions does not fully capture the effect of the disease on
patient QoL [47, 95].
The study by Sato et al. [94] showed that healthcare resource utilization by European pa‐
tients with plaque psoriasis, in terms of dermatologist visits and hospitalizations, is greater
for those with poorer QoL, independent of clinical disease severity, and may decrease if QoL
improves. These authors also found that poor QoL is also associated with employment dis‐
advantages, even when controlling for disease severity, suggesting that indirect costs of
psoriasis may also be augmented for patients who have a poor QoL.
10. QoL in children with psoriasis
In  childhood,  QoL is  greatly  influenced by psoriasis.  Data  on QoL in  juvenile  psoriasis
are  limited,  however  some studies  demonstrated  the  negative  influence  of  psoriasis  on
the QoL of children by means of the Children’s Dermatology Life Quality Index (CDLQI)
[96-100].The  social  development  domain,  which  is  one  of  the  developmental  milestones
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in a child, is particularly impaired [101]. Moreover, psoriasis in childhood causes a high
degree of limitations on recreational activities in at least 15-30% of patients [101]. Itching
and problems with treatments were shown to have the highest impact on the children’s
QoL. The same authors showed that QoL in the long term is not determined by the age
of onset of psoriasis.
Other authors demonstrated that the significant negative impact of plaque psoriasis on QoL
of children with psoriasis is generally comparable to the impact of other serious pediatric
chronic diseases, as arthritis, asthma, and diabetes [102]. The impairment in QoL impacts
particularly emotional and school functioning [102].
11. Impact of psoriasis treatments on QoL
Only a few clinical trials have been conducted on the effect of treatments for psoriasis on
QoL and some of them were not specifically designed to measure QoL but rather inferred
the drug impact on QoL from its effect on the clinical symptoms of the disease.
Among topical treatments, calcipotriol-betamethasone gel was reported to improve QoL in
patients with scalp psoriasis [103]. Narrowband ultraviolet B (NBUVB) phototherapy ad‐
ministered three times a week for 6 months significantly improved QoL in 95 plaque-type
psoriasis patients [104].
Low-dose (3 mg/kg/day), short-term cyclosporine therapy was effective in improving QoL
as measured by Skindex-16 and GHQ-28 in 41 patients with mild to severe psoriasis [105].
An Italian longitudinal study on psoriasis patients followed up for 12 months observed that
treatment with cyclosporine significantly reduced by 30% the risk for minor psychological
distress, while methotrexate and topical corticosteroids were associated with significantly
increased risks (33% and 185%, respectively) [66]. Additionally, results from a small study
indicate that the use of cyclosporine for the treatment of nail psoriasis can lead to an im‐
provement in QoL [106].
In a Canadian randomized, placebo-controlled trial  on 451 plaque psoriasis patients,  vo‐
closporin was reported to improve QoL, assessed by DLQI and Psoriasis Disability Index
(PDI) [107].
A recent analysis of Japanese trials on infliximab demonstrates that a Psoriasis Area and Se‐
verity Index (PASI) 90 response is necessary to achieve a DLQI of 0 or 1. Since infliximab
showed to achieve nearly 50% of PASI 90 responses, the authors infer that it might be useful
in meeting the goal of a DLQI of 0 or 1 [108].
An analysis of pooled data from two randomized, placebo-controlled trials evaluated the ef‐
fects of adalimumab on the risk of symptom worsening in psoriasis and the subsequent im‐
pact on HRQoL. The analysis pointed out that clinically relevant worsening of psoriasis
symptoms was associated with substantial worsening of HRQoL. Adalimumab treatment
was associated with a reduction in risk of clinical worsening of psoriasis, but its specific ef‐
fect on HRQoL was not reported [109].
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A metanalysis of randomized, controlled trials of etanercept in patients with rheumatoid ar‐
thritis, psoriatic arthritis and psoriasis, evaluating among other outcome measures the effect
of the drug on HRQoL, treatment with etanercept resulted in improvements in the physical
and mental component summary scores (PCS and MCS), as well as in individual SF-36 do‐
mains across all indications [110]. The PRESTA trial, conducted in Germany, evaluated the
effect of etanercept on a composite measure of skin symptoms, joint manifestations, and
QoL [111]. At 24 weeks, around 30% of patients met the triad of efficacy outcomes. In juve‐
nile plaque psoriasis, one randomized, controlled, longitudinal study described a significant
positive effect of etanercept on QoL [100].
In a subanalysis of the PHOENIX 1 and 2 trials on ustekinumab in psoriasis, aimed at evalu‐
ating the effect on HRQoL and sexual difficulties, ustekinumab treatment was associated
with significant improvement in HRQoL and sexual difficulties due to psoriasis [112]. An‐
other post-hoc analysis of the PHOENIX 2 trial showed that ustekinumab decreases work
limitations, improves work productivity and reduces work days missed in the 1230 study
patients with moderate-to-severe psoriasis [113]. The efficacy of ustekinumab was also eval‐
uated in nail psoriasis and nail-associated QoL in a population treated for cutaneous psoria‐
sis. Together with a statistically significant reduction of the nail psoriasis severity index
(NAPSI), a significant improvement of the international onychomycosis QoL scores was ob‐
served at all time points up to 40 weeks [114].
In children, in a psoriatic cohort treated in daily clinical practice, QoL was assessed by
CDLQI. The results showed that all psoriasis treatments contributed to a significant im‐
provement in children’s QoL, which was greatest with dithranol and systemic treatments.
The highest positive impact with all treatments was observed on itching and sleep distur‐
bances [115].
12. Conclusions and recommendations for clinical practice
Psoriasis is associated with significant psychological distress, psychiatric morbidity, expe‐
rience of  stigmatization and decreased QoL.  Several  studies  have demonstrated the sig‐
nificant  negative  impact  of  psoriasis  on  QoL,  which  is  similar  to  the  impact  of  other
major chronic diseases as heart diseases, diabetes and cancer. Presence of psoriatic arthri‐
tis,  psychiatric  disorders,  and other co-morbidities may further worsen QoL and should
be taken into account.  The association between symptom severity and QoL,  though ob‐
served by some studies [98,116], is not always strong, and other studies found no signifi‐
cant association at all [48, 95]. Symptom severity has been shown to have a greater direct
impact  on the  physical  rather  than the mental  components  of  QoL,  while  the  effects  of
stigmatization on QoL are more strongly mental [67].  Some research has concluded that
‘subjective experience of psoriasis is a more powerful determinant of QoL’ in comparison
to clinical measures [117].
Studies have shown that dermatologists employ a problem-orientated coping style in caring’
for their patients, and often appear much more interested in investigating the superficial
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skin rather than the deep emotions of their patients [48]. On the contrary, it is essential that
measures of psychosocial morbidity are included when assessing psoriasis severity.
In clinical practice there is a great challenge for dermatologists to improve the QoL of adults
and children with psoriasis. Greater attention should be paid to the possible limitations that
these patients experience. The outcome of QoL measurements should be taken into account
when deciding on treatment strategies. Dermatology professionals should be encouraged to
identify patients, irrespective of gender and of severity of clinical manifestations, who per‐
ceive especially high levels of discomfort, indicate problems in maintaining self-esteem
and/or have experienced instances of rejection. Specific therapeutic strategies that address
issues of self-esteem and social rejection are appropriate especially for these patients. Opti‐
mal therapy that leads to long-lasting remission can only be achieved by addressing both
the physical and psychosocial effects of psoriasis. The choice of the optimal psoriasis treat‐
ment should also take into account the effect of the drug on the patient’s psychosocial well-
being, and adjunctive psychological interventions before and during treatment may be of
benefit for selected patients. It is recommended that psoriasis patients, especially those with
severe disease, receive a more holistic, multitarget approach that encompasses both medical
and psychological measures.
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